Pathologic prognostic factors in stage I-III uterine carcinosarcoma treated with postoperative radiotherapy

Arch Gynecol Obstet. 2014 Aug;290(2):329-34. doi: 10.1007/s00404-014-3202-z. Epub 2014 Mar 15.

Abstract

Purpose: To analyse the impact of prognostic factors on specific overall survival (SOS) after postoperative radiotherapy (P-RT) in carcinosarcomas.

Methods: We retrospectively analysed 81 patients who received P-RT from 1977 to 2010 after the diagnosis of carcinosarcomas. 2009 FIGO stage: 25-IA, 20-IB, 6-II, 9-IIIA, 11-IIIC. Age, stage, vascular and lymphatic space invasion (VLSI), myometrial invasion, grade, mitotic index, sarcomatous/epithelial components, tumour size and necrosis were considered for the analysis.

Statistics: we used the Kaplan-Meier method for survival analysis and the Cox model for risk factor evaluation.

Results: The mean follow-up of the series was 78.86 months (range 7-381). The median age was 72 years (range 51-89). 30 out 81 (37 %) patients relapsed and died (22.2 % pelvic and abdominal, 13.5 % exclusive distant metastasis). On univariate and multivariate analysis only stage had a significant impact on SOS. At 5 years, stage I-II had a SOS of 66 % in comparison with stage III with 30 %.

Conclusions: Two groups of patients showing different outcome were found after P-RT in uterine carcinosarcomas: stage I-II patients had a life expectancy 2.5-fold longer compared to stage III patients. New therapeutic strategies are warranted in carcinosarcomas considering the high incidence of distant metastasis.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Carcinosarcoma* / mortality
  • Carcinosarcoma* / pathology
  • Carcinosarcoma* / radiotherapy
  • Carcinosarcoma* / surgery
  • Combined Modality Therapy
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Staging
  • Prognosis
  • Radiotherapy Dosage
  • Retrospective Studies
  • Survival Analysis
  • Uterine Neoplasms* / mortality
  • Uterine Neoplasms* / pathology
  • Uterine Neoplasms* / radiotherapy
  • Uterine Neoplasms* / surgery